布地奈德福莫特罗吸入剂治疗慢性阻塞性肺疾病的临床效果观察

摘要
图/表
参考文献(15)
相关文章 (7)

全文: PDF (0 KB) HTML (30 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究布地奈德福莫特罗吸入剂治疗慢性阻塞性肺疾病的的临床效果。方法选取2015年8月～2017年8月我院收治的120例慢性阻塞性肺疾病患者为研究对象，按随机数字表法分为实验组和对照组，每组60例。其中对照组采用常规治疗，实验组在常规治疗的基础上辅以布地奈福德莫特罗吸入剂治疗，两组治疗周期均为8周。比较两组患者治疗前后肺功能、6-WMD及治疗期间不良反应发生率，并采用圣乔治呼吸困难问卷（SGRQ）量表和CAT问卷评估两组患者治疗前后的生活质量。结果与治疗前相比，实验组患者的FEV1、FEV1pred%、FEV1/FVC有所降低，6-WMD、SGRQ评分和CAT评分有所改善，差异有统计学意义（P＜0.05）；与治疗前相比，对照组患者的 FEV1、FEV1pred%、FEV1/FVC、6-WMD、SGRQ 评分和 CAT 评分无显著变化，差异无统计学意义（P＞0.05）；治疗后，试验组FEV1、FEV1pred%、FEV1/FVC、6-WMD、SGRQ评分和CAT评分显著优于对照组，差异有统计学意义（P＜0.05)。结论布地奈德福莫特罗吸入剂能有效缓解慢性阻塞性肺疾病患者的临床症状，提高肺功能，改善患者的生活质量，值得临床推广使用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	范艳妮
	孙小琴

关键词 ：慢性阻塞性肺疾病, 布地奈德福莫特罗吸入剂, 治疗结果, 临床观察

Abstract：ObjectiveTo investigate the clinical efficacy of Budesonide Formoterol Inhalant in the treatment of chronic obstructive pulmonary disease.MethodsA total of 120 patients with chronic obstructive pulmonary disease treated in our hospital from August 2015 to August 2017 were selected as the research subjects.The patients were divided into experimental group and control group on the basis of random digital table method,with 60 cases in each group.The control group was given conventional treatment,and the experimental group was supplemented with Budesonide Formoterol Inhalant on the basis of routine treatment.The cycle of treatment was 8 weeks in both groups.The lung function,6-WMD,and the incidence rate of adverse reactions during the treatment were compared between the two groups before and after treatment.The quality of life before and after treatment was evaluated using the St.George′s Respiratory Disease Questionnaire (SGRQ)scale and CAT questionnaire.ResultsCompared with those before treatment,FEV1,FEV1pred%,and FEV1/FVC in the experimental group were decreased,and 6-WMD,SGRQ score and CAT score were improved.Compared with those before treatment,FEV1,FEV1pred%,FEV1/FVC,6-WMD,SGRQ scores and CAT scores in the control group were not significantly different,and the differences were not statistically significant(P＞0.05).After treatment,FEV1,FEV1pred%,FEV1/FVC,6-WMD,SGRQ and CAT scores in the experimental group were significantly better than those in the control group,the differences were statistically significant(P＜0.05).ConclusionBudesonide Formoterol Inhalant can effectively relieve the clinical symptoms of patients with chronic obstructive pulmonary disease,improve lung function and improve the quality of life,which is worthy of clinical promotion and application.

Key words： Chronic obstructive pulmonary disease Budesonide Formoterol Inhalant Treatment results Clinical observation

作者简介: 范艳妮（1982-），女，本科，研究方向：心肺血管疾病

引用本文:

范艳妮; 孙小琴. 布地奈德福莫特罗吸入剂治疗慢性阻塞性肺疾病的临床效果观察[J]. 中国当代医药, 2018, 25(3): 39-41转44.
FAN Yan-ni;SUN Xiao-qin. Observation on the clinical efficacy of Budesonide Formoterol Inhalant in the treatment of chronic obstructive pulmonary disease. 中国当代医药, 2018, 25(3): 39-41转44.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I3/39

[1]	张琼.布地奈德福莫特罗粉吸入剂在稳定期慢性阻塞性肺疾病的临床观察[J].中国药物与临床，2016，16（5）：735-737.
[2]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013，36（4）：484-491.
[3]	姚晓军，刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学，2014，22（8）：1982-1986.
[4]	Ferlay J，Shin HR，Bray F，et al.Estimates of worldwide burden of cancer in 2008：GLOBOCAN 2008[J].Int J Cancer，2010，127（12）：2893-2917.
[5]	Rabe KF，Hurd S，Anzueto A，et al.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease：GOLD executive summary[J].Am J Respir Crit Care Med，2007，176（6）：532-555．
[6]	丁宁，王胜.慢性阻塞性肺疾病发病机制最新研究进展[J].临床肺科杂志，2016，21（1）：133-136.
[9]	Houghton AM.Mechanistic links between COPD and lung cancer[J].Nat Rev Cancer，2013，13（4）：233-245.
[10]	杨雪梅，王卫平.布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病效果分析[J].中国医药，2015，10（11）：1596-1598.
[12]	陈芸.肺癌合并慢阻肺患者生活质量的评价及吸入性药物治疗对其生活质量的影响[D].苏州：苏州大学，2015.
[7]	Putcha N，Drummond MB，Connett JE，et al.Chronic productive cough is associated with death in smokers with early COPD[J].COPD，2014，11（4）：451-458.
[8]	Young RP，Hopkins RJ，Christmas T，et al.COPD prevalence is increased in lung cancer，independent of age，sex and smoking[J].Eur Respiratory J，2009，34（2）：380-386．
[11]	Walters JA，Wang W，Morley C，et al.Different durations of corticosteroidtherapyforexacerbationsofchronicobstructive pulmonary disease[J].Cochrane Database Syst Rev，2014，12（12）：CD006897.
[13]	陈锐，卢火佺.噻托溴胺粉雾剂对稳定期老年慢性阻塞性肺病患者内皮细胞功能的影响及疗效[J].中国老年学，2013，33（20）：5156-5157.
[14]	朱彬.布地奈德福莫特罗吸入剂治疗慢阻肺疾病稳定期疗效观察[J].包头医学，2016，40（4）：202-203.
[15]	刘笑春，马超楠，任争，等.布地奈德/福莫特罗对慢性阻塞性肺疾病稳定期治疗作用的研究[J].中国处方药，2014，12（12）：44-45.